Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial

By sjmartinez • August 31, 2023

Chew KW, Moser C, Yeh E, Wohl DA, Daar ES, Ritz J, Javan AC, Eron JJ, Currier JS, Smith DM, Hughes MD; ACTIV-2/A5401 Study Team. Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial. J Infect Dis. 2023 Aug 31;228(Supplement_2):S83-S91. doi: 10.1093/infdis/jiad300. PMID: 37650237; PMCID: PMC10469584.

Tags: ACTIV-2, covid-19, Harbor UCLA, Infectious Diseases, internal validity, patient-reported outcomes, Publications, symptom diary, time to symptom resolution

Semaglutide and kidney function: direct kidney protection or an artifact?

Ayoub I, Wong G, Glassock RJ. Semaglutide and kidney function: direct kidney protection or an artifact? Kidney Int. 2024 Nov 18:S0085-2538(24)00793-2. doi: 10.1016/j.kint.2024.11.003. Epub ahead[...]

Moving on from clinical animal-derived surfactants to peptide-based synthetic pulmonary surfactant

Walther FJ, Waring AJ. Moving on from clinical animal-derived surfactants to peptide-based synthetic pulmonary surfactant. Am J Physiol Lung Cell Mol Physiol. 2024 Dec 1;327(6):L883-L889.[...]

Influence of Thyroglobulin Autoantibodies on Thyroglobulin Levels Measured by Different Methodologies: IMA, LC-MS/MS, and RIA

Petrovic I, LoPresti J, Fatemi S, Gianoukakis A, Burman K, Gomez-Lima CJ, Nguyen CT, Spencer CA. Influence of Thyroglobulin Autoantibodies on Thyroglobulin Levels Measured by[...]